Lutris Pharma Receives FDA Orphan Drug Designation for LUT014 for the Treatment of EGFRI-Induced Acneiform Rash

Feb. 28, 2024 -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that the U.S. Food and Drug Administration ' s...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials